secwatch.observer — SEC 8-K summary
======================================

Issuer:     Ginkgo Bioworks Holdings, Inc. (DNA)
CIK:        0001830214
Form:       8-K
Filed at:   2022-08-15T23:59:59+00:00
Accession:  0000950170-22-017376
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Ginkgo Q2 revenue $145M (+231% YoY); guides total revenue to $425-440M
----------------------------------------------------------------------

- Foundry revenue $44M (+105% YoY); added 13 new Cell Programs in Q2.
- Biosecurity revenue $100M with 36% gross margin; expects at least $260M for FY 2022.
- Adjusted EBITDA improved to -$23M from -$38M YoY; cash balance ~$1.4B.
- Pending acquisitions of Zymergen (all-stock) and Bayer's West Sacramento facility expected to close Q4 2022 / Q1 2023.
- Dr. Kathy Hopinkah Hannan appointed to board of directors.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1830214/000095017022017376/0000950170-22-017376-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1830214/000095017022017376/dna-20220815.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-017376

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer